Long-acting muscarinic antagonist (LAMA) plus long-acting beta-agonist (LABA) versus LABA plus inhaled corticosteroid (ICS) for stable chronic obstructive pulmonary disease (COPD)-Reference-Cited by-同舟云学术

Long-acting muscarinic antagonist (LAMA) plus long-acting beta-agonist (LABA) versus LABA plus inhaled corticosteroid (ICS) for stable chronic obstructive pulmonary disease (COPD)

Published:2017-02-10 Issue:2 Volume:2018 Page:
ISSN:1465-1858
Container-title:Cochrane Database of Systematic Reviews
language:en
Short-container-title:

Author:

Horita Nobuyuki¹,Goto Atsushi²,Shibata Yuji¹,Ota Erika³,Nakashima Kentaro¹,Nagai Kenjiro¹,Kaneko Takeshi¹

Affiliation:

1. Yokohama City University Graduate School of Medicine; Department of Pulmonology; Fukuura 3-9, Kanazawa Yokohama Japan 236-0004

2. Center for Public Health Sciences, National Cancer Center, Tokyo, Japan; Metabolic Epidemiology Section, Division of Epidemiology; 5-1-1 Tsukiji, Chuo-ku Tokyo Japan 104-0045

3. St. Luke's International University, Graduate School of Nursing Sciences; Global Health Nursing; 10-1 Akashi-cho Chuo-Ku Tokyo Japan 104-0044

Publisher

Wiley

Subject

Pharmacology (medical)

Reference66 articles.

1. The lung function profile of once-daily tiotropium and olodaterol via Respimat is superior to that of twice-daily salmeterol and fluticasone propionate via Accuhaler (ENERGITO study);Beeh;International Journal of Chronic Obstructive Pulmonary Disease,2016

2. Efficacy and safety of umeclidinium/vilanterol (UMEC/VI) once daily (OD) vs fluticasone/salmeterol combination (FSC) twice daily (BD) in patients with moderate-to-severe COPD and infrequent COPD exacerbations;Donohue;Chest,2014

3. Improvements in lung function with umeclidinium/vilanterol versus fluticasone propionate/salmeterol in patients with moderate-to-severe COPD and infrequent exacerbations;Donohue;Respiratory Medicine,2015

4. Efficacy and safety of umeclidinium/vilanterol (UMEC/VI) once daily (OD) vs fluticasone/salmeterol combination (FSC) twice daily (BD) in patients with moderate-to-severe COPD and infrequent COPD exacerbations;Donohue;Chest,2014

5. Improvements in lung function with umeclidinium/vilanterol versus fluticasone propionate/salmeterol in patients with moderate-to-severe COPD and infrequent exacerbations;Donohue;Respiratory Medicine,2015

Cited by 93 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Phenotype to Treatable Traits-Based Management in Chronic Obstructive Pulmonary Disease;Cureus;2024-05-16

2. Treatment with systemic corticosteroid versus placebo for exacerbations of COPD: A systematic review and meta-analysis;Respiratory Investigation;2024-05

3. The clinical characteristics and outcomes of different inhaled therapies in chronic obstructive pulmonary disease patients with frequent cough;Annals of Medicine;2023-12-12

4. Overuse of long-acting β ₂ -agonist/inhaled corticosteroids in patients with chronic obstructive pulmonary disease: time to rethink prescribing patterns;Postgraduate Medicine;2023-11-17

5. Management goals and stable phase management of patients with chronic obstructive pulmonary disease in the Japanese respiratory society guideline for the management of chronic obstructive pulmonary disease 2022 (6th edition);Respiratory Investigation;2023-11